Treatment of ACuTe Coronary Syndromes With Low-dose colchICine

Inclusion Criteria: * Age ≥ 18 years; * Definite diagnosis of ACS; * Ability and willingness to provide written informed consent Exclusion Criteria: * Type 2 myocardial infarction (Patients with symptoms or signs of myocardial ischemia and evidence of increased oxygen demand or decreased supply \[for example, tachyarrhythmia, hypotension, or anaemia\] secondary to an alternative pathology and myocardial necrosis are defined as suffering type 2 myocardial infarction. The classification of type 2 myocardial infarction also includes patients with coronary vasospasm, embolism or spontaneous dissection without evidence of atherothrombosis related to coronary artery disease); * Valvular heart disease that is considered likely to require surgical intervention; * History of non-skin cancer in the past 3 years; * Inflammatory bowel disease or chronic diarrhea; * History of gastric ulcer or previous gastric bleeding; * Neuromuscular diseases or non-transient (At least 2 laboratory tests) creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction); * Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities(Hemoglobin \<100g/L or hematocrit \< 30% or \> 52% or white blood cell count \< 3×109/L or platelet count \< 100×109/L); * Estimated glomerular filtration rate (eGFR)\<30mL/min/1.73m2 (based on CKD-EPI formula); * Serum alanine aminotransferase and/or aspartate aminotransferase levels greater than 2 times the upper limit of the normal range accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders(INR\>1.5)(except for elevated glutamic oxalacetic transaminase associated with myocardial infarction); * Decline in cognitive function due to inability to perform basic activities of daily living independently; * Drug or alcohol abuse; * Other immunosuppressive therapies already in existence or planned; * Other causes require long-term colchicine treatment; * History of clear or suspected colchicine allergy; * Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.